Consistent with observations in CLL patients, treatment of iNHL patients with single-agent GS-1101 or combinations significantly decreased plasma levels of CCL17, CCL22, CXCL13, and TNFα. The gene discussed is CCL22; the disease is B-cell chronic lymphocytic leukemia.